secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001125345-22-000103
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics Q3 net loss narrows to $24.8M; receives $60M Gilead upfront; cash runway into mid-2024
--------------------------------------------------------------------------------

- Q3 total revenue $41.7M (up from $15.7M YoY) including $30M Incyte milestone and $4.4M MARGENZA sales.
- Net loss $24.8M ($0.40/share) vs $52.9M ($0.86/share) in Q3 2021; R&D spend $48.2M.
- Cash $123.6M at Sep 30, plus $60M from Gilead in Oct; cash runway extended into mid-2024.
- Gilead collaboration for MGD024 and up to two bispecific programs; potential $1.7B in milestones plus tiered royalties.
- Teplizumab PDUFA date Nov 17, 2022; if approved, MacroGenics eligible for $60M milestone from Provention Bio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534522000103/0001125345-22-000103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534522000103/mgnx-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001125345-22-000103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer